Aurobindo Pharma Ltd
Aurobindo Pharma Q2 Results 2026 (FY27): Revenue ₹10,263 Cr, PAT ₹1,124 Cr
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Get Aurobindo Pharma Ltd's next results in your feed
Guidance rank: #59 of 85 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Aurobindo Pharma Ltd Q2 FY27 key numbers
- Revenue
- Quarterly revenue for Q2FY27: ₹10,263 Cr, up 23.9% YoY.
As stated in Aurobindo Pharma Ltd's Q2 FY27 investor presentation · published 4 Nov 2026. Reported figures, not investment advice.
Based on Aurobindo Pharma Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Quarterly revenue for Q2FY27: ₹10,263 Cr, up 23.9% YoY (Page 6, 7, 13). EBITDA for Q2FY27: ₹2,156 Cr, a 28.5% year-on-year (YoY) increase (Page 13).
From Aurobindo Pharma Ltd's Q2 FY27 earnings-call transcript · updated 4 Nov 2026.
How did Aurobindo Pharma's revenue grow in the September 2026 quarter?
- Quarterly revenue for Q2FY27: ₹10,263 Cr, up 23.9% YoY (Page 6, 7, 13).
- US Formulations revenue Q2FY27: $477 Mn excluding gRevlimid, up 20% Q-o-Q (Page 10).
- Consolidated revenue from operations Q2FY27: ₹10,263 Cr, compared to ₹8,286 Cr in Q2FY26 (Page 13).
- Gross profit: ₹6,280 Cr, 26.9% YoY growth (Page 13).
- EBITDA: ₹2,156 Cr, up 28.5% YoY, margin 21% (Page 13).
2 more points from Aurobindo Pharma Ltd's call on revenue
Create a free account to keep reading this call
What happened to Aurobindo Pharma's margins in Q2 FY27?
See what Aurobindo Pharma Ltd said on profitability & margins — free account, 30 seconds.
What capex is Aurobindo Pharma planning?
- TheraNym Biologics Facility:
- Combined 120 KL mammalian cell-culture capacity (60 KL Unit 1 + 60 KL Unit 2)
- Unit 1 qualified by March 2027; commissioning and qualification ongoing
- Unit 2 construction began Oct 2026; ready for qualification in 2030
- Estimated capex for Unit 2: USD 180 Mn
- Positioned as a global biologics supply node by 2030
- CuraTeQ Biosimilars & Biologics:
- Capacity expansion adding 10,000 L mammalian cell-culture bioreactors (4 × 2,500 L)
- AuroVaccines merger to add microbial/mammalian drug substance capacity and PFS/vial filling lines by 2027 (on track)
- Other Capex:
- Net Capex of approx. USD 89 million for capability enhancements and new business
- Capex for new business/product development: USD 25 million
2 more points from Aurobindo Pharma Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Aurobindo Pharma raising money or cutting debt?
See what Aurobindo Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Aurobindo Pharma's order book?
Aurobindo Pharma Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹9.2K Cr, net profit ₹1.0K Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Aurobindo Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Unichem Laboratories (Q2 FY27)
Revenue from operations for the quarter ended 30.09.2026 is ₹401.90 crores (standalone) and ₹640.22 crores (consolidated). Key results statement takeaways from
- Zim Laboratories (Q2 FY27)
Total Operating Income for Q2 FY27: ₹1,054 Mn, up 18.9% YoY from ₹887 Mn in Q2 FY26 (Page 5, 10). Key investor presentation takeaways from Zim Laboratories Ltd'
- SMS Pharmaceuticals (Q2 FY27)
Q2FY27 revenue from operations: ₹316.08 crore, a 30% year-on-year (YoY) increase from ₹242.43 crore in Q2FY26 (Page 29, 6). Key investor presentation takeaways
- Biocon Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹4,389 Cr, up 2% YoY . Key investor presentation takeaways from Biocon Ltd's Q2 FY27 investor presentation — and how it ranks a
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Aurobindo Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Aurobindo Pharma Ltd Q2 FY27 results?
Quarterly revenue for Q2FY27: ₹10,263 Cr, up 23.9% YoY (Page 6, 7, 13). EBITDA for Q2FY27: ₹2,156 Cr, a 28.5% year-on-year (YoY) increase (Page 13).
What is Aurobindo Pharma Ltd share price analysis?
Aurobindo Pharma Ltd currently shows a neutral. The stock trades at a P/E of 25.9 with a market cap of ₹98,102 Cr. Investors should review the full earnings analysis for detailed insights.
Is Aurobindo Pharma Ltd planning capital expenditure?
TheraNym Biologics Facility:.
Keep Aurobindo Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.